Guy Van Meter joins Adimab, Inc. as Senior Director, Head of Business Development

Adimab, Inc., a biotechnology company developing an integrated yeast-based antibody discovery and maturation platform, today announced the appointment of Guy Van Meter as Senior Director, Head of Business Development. Mr. Van Meter comes to Adimab from a business development role at Pfizer Inc, where he was involved in new business initiatives around RNAi therapeutics and regenerative medicine for Pfizer’s Biotherapeutics and Bioinnovation Center in San Francisco.

Prior to Pfizer, Mr. Van Meter spent 6 years in business development at Dyax Corp, including managing Dyax’s successful phage display licensing program. At Dyax, he established more than 45 revenue-generating collaborations with companies in the United States, Europe, India, Australia, and Japan, including Amgen, Boehringer-Ingelheim, Merck-Serono, and ImClone.

Prior to Dyax, Mr. Van Meter held regulatory and research roles at Alkermes, Inc, and conducted research at Harvard’s Brigham and Women’s and Yale University. He graduated from the Olin Graduate School of Business at Babson College in 2002.

“Adimab is at a critical juncture where the number of potential collaborations exceeds our current capacity,” said Tillman Gerngross Ph.D., Adimab’s co-founder and Chief Executive Officer. ”Managing multiple relationships with several large companies and ensuring a quality experience is of great importance to us. Guy Van Meter comes to Adimab with a wealth of experience in Business Development, in particular in the antibody space, and we are delighted to have him join the team.”

“Adimab is one of the most impressive companies to enter the antibody technology space in some time,” said Mr. Van Meter. “The company’s approach is clearly unique and provides advantages over all existing technologies. I am very pleased to joining a company with such an experienced management team and talented scientists. It is an exciting time.”

About Adimab, Inc.

Adimab is changing the discovery, maturation and production of therapeutic human antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. Our proprietary library design and presentation technology allows us to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology.

Contact

Errik B. Anderson
VP Operations & Finance
Adimab, Inc.
(603) 727-7107
errik.anderson@adimab.com